Movatterモバイル変換

Azelastin

С Википедије, слободне енциклопедије

Azelastin
Klinički podaci

Prodajno ime	Astelin, Optivar
Drugs.com	Monografija
Način primene	Oftalmički, nazalno
Farmakokinetički podaci
Poluvreme eliminacije	22 h
Izlučivanje	Fekalno

Identifikatori
CAS broj	58581-89-8^Y
ATC kod	R01AC03 (WHO),S01GX07
PubChem	CID2267
DrugBank	DB00972^Y
ChemSpider	2180^Y
KEGG	C07768^Y
ChEBI	CHEBI:2950^Y
ChEMBL	CHEMBL639^Y
Hemijski podaci
Formula	C₂₂H₂₄ClN₃O
Molarna masa	381,898
SMILES CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O
InChI InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3^Y Key:MBUVEWMHONZEQD-UHFFFAOYSA-N^Y

Fizički podaci
Tačka topljenja	225 °C (437 °F)

Azelastin jeorgansko jedinjenje, koje sadrži 22atoma ugljenika i imamolekulsku masu od 381,898Da.^[1]^[2]^[3]^[4]

Osobine

[уреди |уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	0
Broj rotacionih veza	3
Particioni koeficijent^[5] (ALogP)	4,1
Rastvorljivost^[6] (logS, log(mol/L))	-5,7
Polarna površina^[7] (PSA,Å²)	35,9

Reference

[уреди |уреди извор]

^Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis.Horak, F. (2008 Oct).„Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis”.Ther Clin Risk Manag.4 (5): 1009—22.PMC 2621402 .PMID 19209282.doi:10.2147/tcrm.s3229 . Проверите вредност парамет(а)ра за датум:|date= (помоћ)
^Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability.Bernstein, J. A. (2007 Oct). „Azelastine hydrochloride: A review of pharmacology, pharmacokinetics, clinical efficacy and tolerability”.Curr Med Res Opin.23 (10): 2441—52.PMID 17723160.doi:10.1185/030079907X226302. Проверите вредност парамет(а)ра за датум:|date= (помоћ)
^Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011).„DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”.Nucleic Acids Research.39 (Database issue): D1035—D1041.PMC 3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.
^Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008).„DrugBank: A knowledgebase for drugs, drug actions and drug targets”.Nucleic Acids Research.36 (Database issue): D901—D906.PMC 2238889 .PMID 18048412.doi:10.1093/nar/gkm958.
^Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”.The Journal of Physical Chemistry A.102 (21): 3762—3772.Bibcode:1998JPCA..102.3762G.doi:10.1021/jp980230o.
^Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Journal of Chemical Information and Computer Sciences.41 (6): 1488—1493.PMID 11749573.doi:10.1021/ci000392t.
^Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”.Journal of Medicinal Chemistry.43 (20): 3714—3717.PMID 11020286.doi:10.1021/jm000942e.